Targeting SOX13 Inhibits Assembly of Respiratory Chain Supercomplexes to Overcome Ferroptosis Resistance in Gastric Cancer

Hui Yang,Qingqing Li,Xingxing Chen,Mingzhe Weng,Yakai Huang,Qiwen Chen,Xiaocen Liu,Haoyu Huang,Yanhuizhi Feng,Hanyu Zhou,Mengying Zhang,Weiya Pei,Xueqin Li,Qingsheng Fu,Liangyu Zhu,Yingying Wang,Xiang Kong,Kun Lv,Yan Zhang,Yangbai Sun,Mingzhe Ma
DOI: https://doi.org/10.1038/s41467-024-48307-z
IF: 16.6
2024-01-01
Nature Communications
Abstract:Therapeutic resistance represents a bottleneck to treatment in advanced gastric cancer (GC). Ferroptosis is an iron-dependent form of non-apoptotic cell death and is associated with anti-cancer therapeutic efficacy. Further investigations are required to clarify the underlying mechanisms. Ferroptosis-resistant GC cell lines are constructed. Dysregulated mRNAs between ferroptosis-resistant and parental cell lines are identified. The expression of SOX13/SCAF1 is manipulated in GC cell lines where relevant biological and molecular analyses are performed. Molecular docking and computational screening are performed to screen potential inhibitors of SOX13. We show that SOX13 boosts protein remodeling of electron transport chain (ETC) complexes by directly transactivating SCAF1. This leads to increased supercomplexes (SCs) assembly, mitochondrial respiration, mitochondrial energetics and chemo- and immune-resistance. Zanamivir, reverts the ferroptosis-resistant phenotype via directly targeting SOX13 and promoting TRIM25-mediated ubiquitination and degradation of SOX13. Here we show, SOX13/SCAF1 are important in ferroptosis-resistance, and targeting SOX13 with zanamivir has therapeutic potential. The ability of anti-cancer therapies such as radiotherapy, chemotherapy and immunotherapy to induce ferroptosis has been linked to their efficacy. Here, the authors demonstrate that SOX13 promotes ferroptosis-resistance via transactivation of SCAF1, identifying SOX13 as a targeted therapeutic vulnerability in gastric cancer.
What problem does this paper attempt to address?